1100P Restricted mean survival time (RMST) and cure-rate modeling in estimating survival benefit with adjuvant dabrafenib (D) plus trametinib (T) treatment in melanoma
John M. Kirkwood(UPMC Hillman Cancer Center), Mario Mandalà(University of Perugia), Jacob Schachter, Marta Nyakas(Oslo University Hospital), Dirk Schadendorf(National Center for Tumor Diseases), Monique Tan(Heidelberg University), Axel Hauschild(University Hospital Schleswig-Holstein), Hiya Banerjee(Tris Pharma (United States)), T Haas(Novartis (United States)), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Mike Lau(Novartis (Switzerland)), Georgina V. Long(The University of Sydney), James Larkin(Trinity College Dublin), Laurent Mortier, Mario Santinami(Fondazione IRCCS Istituto Nazionale dei Tumori), Reinhard Dummer(University Hospital of Zurich), Andrew Haydon(The Alfred Hospital), Caroline Robert(Institut Gustave Roussy), Victoria Atkinson(Greenslopes Private Hospital)
Cited by 1
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k